Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2777)	11/13/1997 11:43:00 PM
From: Joe E.	Respond to of 6136

Re Alex Brown recommendation, especially this: <<--Specifically, total Viracept prescriptions captured by IMS America for the month of October were 41,085, up 9.5% sequentially. For this entire class of drugs, which includes Viracept, Merck's Crixivan, Roche's Invirase and Abbott's Norvir, total prescriptions for the month of October were 143,402, up 6.0% sequentially. Importantly, Viracept continued to gain market share within this class of drugs; Viracept's market share increased from 27.7% in September to 28.7% in October, while Crixivan's market share remained flat at 41.1%.>> The NIH thinks 650,000 to 900,000 people were living with HIV infection in 1996 in the U. S.. From the IMS data it looks like maybe something like one third to one fourth of them are being treated with protease inhibitors. I also understand that the infection continues to spread The 6% monthly growth of the use of protease inhibitors in the U. S. could go on for a long time.

To: JOHN W. who wrote (2777)	11/14/1997 9:54:00 AM
From: cherry grove	Read Replies (1) \| Respond to of 6136

I think we have seen the "abyss". Thanks John W. for all your due diligence and great information.. I was about ready to give up and take my losses. Hopefully, with some "pounding on the table" by analysts, Agouron will soon get a quick "jump start". Quite frankly I would be pleased with 64 price target in twelve months and then a 1000 next year. Cherry